Literature DB >> 29683096

Novel Anthraquinone Derivatives as Dual Inhibitors of Topoisomerase 2 and Casein Kinase 2: In Silico Studies, Synthesis and Biological Evaluation on Leukemic Cell Lines.

Abbas Kabir1, Kalpana Tilekar1, Neha Upadhyay1, C S Ramaa1.   

Abstract

BACKGROUND: Cancer being a complex disease, single targeting agents remain unsuccessful. This calls for "multiple targeting", wherein a single drug is so designed that it will modulate the activity of multiple protein targets. Topoisomerase 2 (Top2) helps in removing DNA tangles and super-coiling during cellular replication, Casein Kinase 2 (CK2) is involved in the phosphorylation of a multitude of protein targets. Thus, in the present work, we have tried to develop dual inhibitors of Top2 and CK2.
OBJECTIVE: With this view, in the present work, 2 human proteins, Top2 and CK2 have been targeted to achieve the anti-proliferative effects.
METHODS: Novel 1-acetylamidoanthraquinone (3a-3y) derivatives were designed, synthesized and their structures were elucidated by analytical and spectral characterization techniques (FTIR, 1H NMR, 13C NMR and Mass Spectroscopy). The synthesized compounds were then subjected to evaluation of cytotoxic potential by the Sulforhodamine B (SRB) protein assay, using HL60 and K562 cell lines. Ten compounds were analyzed for Top2, CK2 enzyme inhibitory potential. Further, top three compounds were subjected to cell cycle analysis.
RESULTS: The compounds 3a to 3c, 3e, 3f, 3i to 3p, 3t and 3x showed excellent cytotoxic activity to HL-60 cell line indicating their high anti-proliferative potential in AML. The compounds 3a to 3c, 3e, 3f, 3i to 3p and 3y have shown good to moderate activity on K-562 cell line. Compounds 3e, 3f, 3i, 3x and 3y were found more cytotoxic than standard doxorubicin. In cell cycle analysis, the cells (79-85%) were found to arrest in the G0/G1 phase.
CONCLUSION: We have successfully designed, synthesized, purified and structurally characterized 1- acetylamidoanthraquinone derivatives. Even though our compounds need design optimization to further increase enzyme inhibition, their overall anti-proliferative effects were found to be encouraging. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Dual targeting; anthraquinone; anti-cancer; casein kinase 2; leukemic cell line; topoisomerase 2.

Mesh:

Substances:

Year:  2018        PMID: 29683096     DOI: 10.2174/1871520618666180423111309

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  5 in total

1.  Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.

Authors:  Kalpana Tilekar; Neha Upadhyay; Jessica D Hess; Lucasantiago Henze Macias; Piotr Mrowka; Renato J Aguilera; Franz-Josef Meyer-Almes; Cristina V Iancu; Jun-Yong Choe; C S Ramaa
Journal:  Eur J Med Chem       Date:  2020-07-02       Impact factor: 6.514

2.  Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.

Authors:  Neha Upadhyay; Kalpana Tilekar; Niklas Jänsch; Markus Schweipert; Jessica D Hess; Luca Henze Macias; Piotr Mrowka; Renato J Aguilera; Jun-Yong Choe; Franz-Josef Meyer-Almes; C S Ramaa
Journal:  Bioorg Chem       Date:  2020-05-15       Impact factor: 5.275

3.  Hypoglycemic and Hypolipidemic Swords: Synthesis and In-vivo Biological Assessment of 5-benzylidene-2,4-thiazolidinediones.

Authors:  Vijay Patil; Neha Upadhyay; Kalpana Tilekar; Hardik Joshi; C S Ramaa
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

4.  Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells.

Authors:  Kalpana Tilekar; Neha Upadhyay; Markus Schweipert; Jessica D Hess; Lucasantiago Henze Macias; Piotr Mrowka; Franz-Josef Meyer-Almes; Renato J Aguilera; Cristina V Iancu; Jun-Yong Choe; C S Ramaa
Journal:  Eur J Pharm Sci       Date:  2020-08-12       Impact factor: 5.112

5.  Development of 1,2,4-Triazole-5-Thione Derivatives as Potential Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) in Tuberculosis.

Authors:  Dhagash Vora; Neha Upadhyay; Kalpana Tilekar; Viral Jain; C S Ramaa
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.